Jamjoom Pharmaceuticals Factory Company

SASE:4015 Stock Report

Market Cap: ر.س10.8b

Jamjoom Pharmaceuticals Factory Valuation

Is 4015 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 4015 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 4015 (SAR154.8) is trading above our estimate of fair value (SAR106.08)

Significantly Below Fair Value: 4015 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 4015?

Key metric: As 4015 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 4015. This is calculated by dividing 4015's market cap by their current earnings.
What is 4015's PE Ratio?
PE Ratio31x
Earningsر.س349.40m
Market Capر.س10.84b

Price to Earnings Ratio vs Peers

How does 4015's PE Ratio compare to its peers?

The above table shows the PE ratio for 4015 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average62.6x
2070 Saudi Pharmaceutical Industries and Medical Appliances
160.5x35.1%ر.س3.7b
4016 Middle East Pharmaceutical Industries
30.5xn/aر.س2.5b
506943 J. B. Chemicals & Pharmaceuticals
44.1x19.4%₹269.3b
000623 Jilin Aodong Pharmaceutical Group
15.4x38.1%CN¥22.1b
4015 Jamjoom Pharmaceuticals Factory
31x11.2%ر.س10.8b

Price-To-Earnings vs Peers: 4015 is good value based on its Price-To-Earnings Ratio (31x) compared to the peer average (62.6x).

Price to Earnings Ratio vs Industry

How does 4015's PE Ratio compare vs other companies in the Asian Pharmaceuticals Industry?

12 CompaniesPrice / EarningsEstimated GrowthMarket Cap
4015 31.0xIndustry Avg. 24.0xNo. of Companies73PE020406080100+
12 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 4015 is expensive based on its Price-To-Earnings Ratio (31x) compared to the Asian Pharmaceuticals industry average (24.1x).

Price to Earnings Ratio vs Fair Ratio

What is 4015's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

4015 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio31x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate 4015's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 4015 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentر.س154.80
ر.س174.38
+12.6%
2.3%ر.س180.00ر.س169.50n/a4
Nov ’25ر.س169.00
ر.س172.94
+2.3%
3.5%ر.س180.00ر.س163.75n/a4
Oct ’25ر.س185.80
ر.س172.94
-6.9%
3.5%ر.س180.00ر.س163.75n/a4
Sep ’25ر.س177.40
ر.س162.25
-8.5%
9.3%ر.س180.00ر.س143.00n/a3
Aug ’25ر.س155.20
ر.س146.62
-5.5%
5.0%ر.س156.86ر.س140.00n/a3
Jul ’25ر.س144.60
ر.س146.62
+1.4%
5.0%ر.س156.86ر.س140.00n/a3
Jun ’25ر.س132.60
ر.س146.62
+10.6%
5.0%ر.س156.86ر.س140.00n/a3
May ’25ر.س133.00
ر.س142.10
+6.8%
1.1%ر.س143.31ر.س140.00n/a3
Apr ’25ر.س128.80
ر.س132.10
+2.6%
7.2%ر.س143.31ر.س120.00n/a3
Mar ’25ر.س144.40
ر.س118.28
-18.1%
10.8%ر.س133.00ر.س101.85n/a3
Feb ’25ر.س138.60
ر.س118.28
-14.7%
10.8%ر.س133.00ر.س101.85n/a3
Jan ’25ر.س114.60
ر.س118.28
+3.2%
10.8%ر.س133.00ر.س101.85n/a3
Dec ’24ر.س114.00
ر.س118.28
+3.8%
10.8%ر.س133.00ر.س101.85n/a3
Nov ’24ر.س108.40
ر.س115.28
+6.3%
11.8%ر.س134.00ر.س101.85ر.س169.003
Oct ’24ر.س118.40
ر.س115.28
-2.6%
11.8%ر.س134.00ر.س101.85ر.س185.803
Sep ’24ر.س116.20
ر.س122.00
+5.0%
9.8%ر.س134.00ر.س110.00ر.س177.402
Aug ’24ر.س120.80
ر.س122.00
+1.0%
9.8%ر.س134.00ر.س110.00ر.س155.202

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies